- Prothena to receive $80 million from Bristol Myers Squibb for exclusive US license to PRX005; Next option for worldwide rights following completion of Phase 1
- PRX005 is an investigational best-in-class anti-tau antibody targeting the microtubule binding region of tau for the treatment of Alzheimer’s disease
- Phase 1 study has initiated
Slingshot members are tracking this corporate initiative:
Prothena (PRTA) Announces Bristol Myers Squibb (BMY) Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Jun 24, 2021 Projected Implementation: Q3, 2021 Relevance Tracked Until: Q4, 2021
Don’t see a project related to the strategic initiative you care about?
Related Keywords Anti-tau Prx005, Alzheimer's Disease